Detection of small dense LDL-cholesterol: Is it necessary to determine particle size?

Future Lipidology

Volumn 3, Issue 1, 2008, Pages 23-25

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Insulin resistance; Metabolic syndrome; Small dense LDL; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; C PEPTIDE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AGE; ARTICLE; ATHEROGENESIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; GENDER; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 40749103679     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.1.23     Document Type: Article

References (21)

1. Julius U, Dittrich M, Pietzsch J: Factors influencing the formation of small dense low-density lipoprotein particles in dependence on the presence of the metabolic syndrome and on the degree of glucose intolerance. Int. J. Clin. Pract. 61(11), 1798-1804 (2007).
2. Anderson KM, Odell PM, Wilson PW et al.: Cardiovascular disease risk profiles. Am. Heart J. 121(1 Pt 2), 293-298 (1991).
3. Assmann G, Schulte H: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am. J. Cardiol. 70(7), 733-737 (1992).
4. Sarwar N, Danesh J, Eiriksdottir G et al.: Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115(4), 450-458 (2007).
5. Walldius G, Jungner I, Holme I et al.: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358(9298), 2026-2033 (2001).
6. Ingelsson E, Schaefer EJ, Contois JH et al.: Clinical utility of different measures for prediction of coronary heart disease in men and women. JAMA 298(7), 776-785 (2007).
7. Austin MA: Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr. Atheroscler. Rep. 2(3), 200-207 (2000).
8. Lemieux I, Pascot A, Couillard C et al.: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102(2), 179-184 (2000).
9. Rizzo M, Berneis K: Who needs to care about small, dense low-density lipoproteins? Int. J. Clin. Pract. 61(11), 1949-1956 (2007).
10. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276(11), 875-881 (1996).
11. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3(2), 213-219 (1996).
12. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19), 2486-2497 (2001).
13. Ensign W, Hill N, Heward CB: Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin. Chem. 52(9), 1722-1727 (2006).
14. Otvos JD, Collins D, Freedman DS et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113(12), 1556-1563 (2006).
15. Wilson PWF, Myers GL, Cooper GR et al.: Lipoprotein subclasses and particle size and CVD risk. In: The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers of Cardiovascular Disease and Stroke. Myers CL, Christenson RH, Cushman M et al. (Eds). American Association for Clinical Chemistry, Washington DC, USA 42-46 (2006).
16. St-Pierre AC, Cantin B, Dagenais GR et al.: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol. 25(3), 553-559 (2005).
17. Campos H, Perlov D, Khoo C et al.: Distinct patterns of lipoproteins with ApoB defined by presence of ApoE or ApoC-III in hypercholesterolemia and hypertriglyceridemia. J. Lipid Res. 42(8), 1239-1249 (2001).
18. Chan D, Ooi E, Watts GF: An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor? Int. J. Clin. Pract. (2008) (In Press).
19. Sacks FM, Alaupovic P, Moye LA et al.: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 102(16), 1886-1892 (2000).
20. Robins SJ, Collins D, Wittes JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285(12), 1585-1591 (2001).
21. Saha SA, Kizhakepunnur LG, Bahekar A et al.: The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am. Heart J. 154(5), 943-953 (2007).